| NEWS
news G
lobal reGenerative medicine
company,
mesoblast limited, (aSX: mSb), has announced that it has received clearance from the european medicines agency
(ema) to begin a 225-patient multi-centre Phase 2 clinical trial in europe for its lead cardiovascular product revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. revascor™ is an allogeneic adult stem cell product derived from mesoblast's proprietary mesenchymal Precursor cell (mPc) platform technology, which is being developed for use in a range of cardiovascular diseases. the placebo-controlled Phase 2 trial, amici
(allogeneic mesenchymal precursor cell infusion in myocardial infarction), is approved under europe's voluntary harmonisation procedure and will initially recruit patients from the UK, the netherlands and belgium. trial recruitment is subsequently expected to involve sites in additional european nations, australia,
A SURVEY
commissioned by the American Society of Aesthetic Plastic
Surgery (ASAPS) found that
the number of Americans who approve of cosmetic plastic surgeries is increasing, regardless of age and income level. The survey also revealed that men and women between the ages of 18 and 24 years are the most likely to consider undergoing procedures themselves — either immediately or in the future — even
A round-up of news stories in the aesthetic and anti-ageing medicine industry
StEm-cEll hEArt trEAtmENt rEcEivES cliNicAl triAl go-AhEAd
and the US. the primary endpoint of the study will be safety and efficacy at 6 months in heart attack patients who will receive either revascor™ at one of two doses or placebo. durability of effect will additionally be monitored for up to 36 months. Heart attacks remain
the biggest killer of people in the industrialised world. every year, over 1.7 million people have a heart attack in europe, and over 1.1 million in the US. most patients undergo an early angioplasty of the blocked artery accompanied by implantation of a metal stent to keep the artery open long-term. However, a significant number of the surviving patients subsequently become disabled with heart failure.
revascor™ is injected by a simple
intracoronary infusion at the same time as the angioplasty and stent procedure, within 12 hours of the heart attack. in preclinical trials, a simple intracoronary infusion of mesoblast’s mPcs increased the number of blood vessels in the infarcted region, prevented scar formation, and significantly improved heart muscle function after a heart attack, preventing heart failure. 'the preclinical data were very compelling, and formed the basis for this innovative clinical trial,' said the study’s Principal investigator, Professor eric duckers.
'We are excited to be pioneering a
novel and minimally invasive clinical approach that has the potential to greatly improve the quality of life for patients suffering acute heart attacks,' Professor duckers added.
MANY YOUNG WOMEN PLAN PLASTIC SURGERIES IN TEENS RECENT
though the majority of individuals choosing plastic surgeries are actually aged between 35 and 50 years. Additionally, a pair of studies
conducted in the UK reveal that young women often decide at an early age to seek out surgeries to enhance their appearance. According to Spire Healthcare, a British plastic surgery group, a survey of 3000 women between the ages of 18 and 30 years revealed that 25% of women first consider cosmetic procedures between the ages of 10 and 15 years old.
As they age, even more plan to go under the knife. The survey found that one in three British teens decide to pursue plastic surgeries between the ages of 15 and 18 years. A separate poll of 1000 women aged between 18 and 30 conducted by More magazine revealed similar findings. Of those questioned, 72% said they want to
have
cosmetic surgery and 49% said they are planning to
have
work done at some point in the near future.
More than half of those who plan future surgeries (57%) say they will do so because they are unhappy with the way they look. According to
the ASAPS,
common surgeries undergone by those under the age of 35 years include breast augmentation, liposuction and rhinoplasty. Non-surgical procedures such as botulinum toxin injections, hyaluronic acid injections, microdermabrasio,n and laser hair removal are also common among younger patients.
prime-journal.com | October 2011 ❚ 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84